What side effects are associated with this type of intervention?

Common treatments for neurologic symptoms include medications like memantine, antiseizure medications, and monoamine oxidase inhibitors, as well as physical interventions such as exercise. Memantine is associated with cognitive adverse events and no significant improvement in clinical status. Antiseizure medications like valproate and carbamazepine may reduce agitation but lack convincing evidence of efficacy. Monoamine oxidase inhibitors like selegiline can improve behavior but have limited evidence. Physical activity, similar to the 'Exercise Snacks' trial, generally has fewer side effects and can improve muscle metabolism and overall physical health.

What prior FDA approvals exist?

FDA-approved treatments for neurologic symptoms include medications like gabapentin and tricyclic antidepressants, which are used to manage pain associated with polyneuropathy. For multiple sclerosis, dalfampridine (Ampyra) is approved to improve walking in patients, which indirectly supports muscle function. While there are no specific FDA approvals for 'exercise snacks' or intermittent physical activity to improve muscle metabolism, physical therapy and exercise are commonly recommended as part of the management plan for various neurologic conditions to enhance muscle function and overall metabolic health.

What other types of research exist?

Promising alternatives to Exercise Snacks for improving muscle metabolism in patients with neurologic symptoms include: 1) High-intensity interval training (HIIT), which has been shown to enhance muscle function and metabolic health. 2) Progressive resistance training, which can improve muscle strength and reduce symptoms in conditions like Parkinson's disease and amyotrophic lateral sclerosis. 3) Neuromuscular electrical stimulation (NMES), which can stimulate muscle activity and improve muscle mass and function. 4) Personalized nutrition plans focusing on high-protein and anti-inflammatory diets to support muscle health and reduce neurologic symptoms.

← Back to Search

Exercise Snacks for Sarcopenia

N/A

Recruiting

Led By Daniel R Moore, PhD

Research Sponsored by University of Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 hours

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if doing simple exercises like standing up from a chair and raising heels can help older adults maintain muscle health during periods of low activity. The goal is to see if these exercises help muscles use food nutrients better and prevent muscle loss. The study focuses on adults over 50 who are at risk of losing muscle strength and function.

Who is the study for?

This trial is for healthy older adults aged 60-80 with a BMI of 18.5-29.9, who can follow the study's rules like not walking more than 1,500 steps/day during part of the study. People with recent cancer, chronic illnesses like heart disease or diabetes, those using walkers or tobacco, and those on certain medications like anticoagulants can't join.

What is being tested?

The trial tests if doing 'exercise snacks' (15 chair stands with calf raises every half hour) can help maintain muscle health when older adults have been less active (<1500 steps/day) for three days.

What are the potential side effects?

Since this intervention involves light physical activity, potential side effects may include muscle soreness or fatigue. However, as it's designed for older individuals without major health issues, serious side effects are unlikely.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Myofibrillar protein synthesis rates

Secondary study objectives

Amino acid oxidation and net protein balance

Postprandial glucose area under the curve (AUC) to mixed macronutrient breakfast

Postprandial insulin area under the curve (AUC) to mixed macronutrient breakfast

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Step-ReductionExperimental Treatment2 Interventions

Participants will undergo three days of reduced physical activity (\<1,500 steps/day) prior to a metabolic trial to establish their anabolic response to a protein-carbohydrate meal.

Group II: Habitual ActivityExperimental Treatment1 Intervention

Following three days of habitual activity, a metabolic trial will be completed wherein participants (10M/10F) will be assessed for their anabolic response to a protein-carbohydrate meal.

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for neurologic symptoms include medications like Carbamazepine, which stabilizes nerve activity by reducing abnormal electrical discharges in the brain, and physical exercise, which improves muscle metabolism and overall neurological function. The 'Exercise Snacks' study highlights the benefits of intermittent physical activity, such as chair stands with calf raises, in enhancing skeletal muscle metabolic health. Understanding these mechanisms is crucial for patients as it helps tailor treatments that not only alleviate symptoms but also improve overall neurological health and quality of life.

Treatment outcome and complications in patients treated for malignant epidural spinal cord compression (SCC).Anticholinergics in adult-onset focal dystonia.A case of mixed type of paroxysmal dyskinesia: is there an overlap between two clinical categories of paroxysmal dyskinesia?